Entyvio (vedolizumab) — Intravenous infusion medical benefit policy
Customize your policy alerts
Sign up for sierra health and life Policy 2026D0053Q alerts
Get alerted when Policy 2026D0053Q changes without checking for updates manually.
Monitor payer policy activity
Medical policy governing medical-benefit coverage and prior authorization criteria for intravenously administered Entyvio (vedolizumab) for UnitedHealthcare Commercial and Individual Exchange plans.
Coverage criteria were revised to require either prior failure of specified conventional therapies or prior treatment with a systemic targeted immunomodulator for initial therapy in Crohn's disease and ulcerative colitis.
Continuation criteria now require that patients are not receiving Entyvio in combination with another systemic targeted immunomodulator for the same indication.
Previous requirements for failure of at least one TNF blocker, immunomodulator, or corticosteroid for some indications were removed.
List of systemic targeted immunomodulators that must not be used in combination with Entyvio was updated (e.g., Zeposia added; some agents removed).
Policy template updated and Application section added specifying applicability to UnitedHealthcare Commercial and Individual Exchange benefit plans.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.